Celadon Capital

What Celadon Capital does

Celadon Capital is a private investment firm headquartered in Kuala Lumpur, Malaysia, founded in 1996. Its self-described business is venture capital and the provision of services to businesses globally, with no publicly disclosed portfolio composition, AUM, headcount, fee structure, or product offering. Core technology, pricing model, and distribution channels are listed as not publicly disclosed, consistent with a small or opaque private investment vehicle rather than an institutionalized asset manager.

The firm's most substantive documented activity is its role as the largest investor in Senti Biosciences Holdings Inc. and its control, through affiliates, of a July 15, 2026 strategic transaction in which Senti's Gene-Circuit-enabled pipeline — including the SENTI-202 therapy — was transferred into a newly formed private biotechnology company. Senti Biosciences stockholders received Contingent Value Rights (CVRs) providing up to $60 million in milestone payments over seven years, tied to future development, regulatory, and commercial success of SENTI-202. This positions Celadon as a controlling investor with the ability to develop innovative biotech assets outside the public company structure, and as the architect of a structured milestone-based deal instrument.

The business model implied by the available data is that of an investor that underwrites concentrated positions in individual assets, structures bespoke transaction vehicles (such as the new private biotech and CVR mechanism), and absorbs long-duration regulatory and commercial milestone risk in exchange for control economics. There is no evidence of recurring fee-based revenue, a diversified portfolio, or operating subsidiaries beyond the controlled Senti Bio pipeline carve-out. Customer segmentation is described as horizontal with a single identified use case — investment in and acquisition of gene therapy assets — indicating that, within the limits of public information, Celadon's current strategic focus is narrowly concentrated in biotech asset acquisition and spin-off transactions.

Name

Celadon Capital

Website

https://celadon.asia

Company type

Private

Founded year

1996

Operating status

Operating

Short description

Celadon Capital is a Kuala Lumpur-based private investment firm founded in 1996 that provides venture capital and business services globally, most notably acting as the largest investor in Senti Biosciences and controlling the 2026 spin-off of its gene-circuit pipeline into a new private biotech with milestone-linked CVR terms.

Ownership category

akta.pro rank

Product category

Venture Capital & Private Equity

NAICS

Portfolio Management and Investment Advice (523940), Other Financial Investment Activities (5239)

SIC

Investment Advice (6282)

akta.pro primary industry

Strategic / Balance-Sheet CVC (On-balance-sheet investing) (FSANAHAA)

akta.pro secondary industry

Captive CVC Fund (Dedicated corporate fund structure) (FSANAHAB)

Keywords

• Venture capital
• Private equity
• Biotech investment
• Asset acquisition
• Contingent value rights

Headquarters

HQ city

Kuala Lumpur

HQ country

Malaysia

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Others

Core offering

Celadon Capital is a private investment firm that provides venture capital and investment services to businesses worldwide. The firm operates as a financial investor, most notably controlling a newly formed private biotechnology company that acquired Senti Biosciences' Gene-Circuit-enabled pipeline, including the SENTI-202 therapy, in a structured spin-off transaction.

Differentiator

Problem solved

Functional benefit

Products and services

• Biotech Asset Acquisition and Spin-off Investment

Quantifiable outcome

• Up to $60 million in milestone payments over seven years tied to SENTI-202 development

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights4 records

Direct peers

• RA Capital Management: Healthcare-focused investment manager with both public and private exposure, including structured equity and milestone-based deals. Comparable for its willingness to underwrite binary clinical and regulatory outcomes.
• 5AM Ventures: Biotech-specialist venture firm focused on early-stage therapeutic platforms. Comparable in fund structure, biotech underwriting approach, and tendency to take board-level control of portfolio companies.
• OrbiMed Advisors: Healthcare-dedicated investment firm across venture, growth, and credit. Comparable as a healthcare-specialist investor that underwrites clinical risk and takes meaningful ownership stakes in therapeutic pipelines.
• ARCH Venture Partners: Long-tenured US biotech-focused venture firm with deep exposure to early-stage and clinical-stage therapeutic platforms. Directly comparable as a VC taking controlling or large ownership positions in biotech asset carve-outs and platform companies.
• Atlas Venture: Early-stage biotech-focused venture firm that builds and controls portfolio companies around specific therapeutic programs. Directly comparable as a specialist VC forming and governing private biotech vehicles.

Broad incumbents

• Khosla Ventures: Broad-spectrum venture firm with active biotech and therapeutic platform investing. Comparable in taking concentrated, high-conviction positions in transformational life sciences opportunities.
• Bain Capital Life Sciences: Healthcare-dedicated arm of a major private investment firm with biotech focus. Comparable as an institutional investor underwriting biotech asset carve-outs and clinical-stage risk.
• New Enterprise Associates (NEA): Large diversified venture firm with significant healthcare and biotech practice. Comparable as a multi-stage VC capable of leading complex biotech and life sciences transactions at scale.

Emerging players

• CRISPR Therapeutics: Clinical-stage gene-editing biotech developing programmable cell therapies. Comparable as a gene-circuit-adjacent therapeutic platform relevant to Celadon's controlled SENTI-202 pipeline.

Regional players

• Temasek Holdings: Singapore-based long-term strategic investor with global biotech and life sciences exposure. Comparable as an Asia-headquartered strategic investor deploying cross-border capital into healthcare and biotech.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/CeladonCapital
• Facebookfacebook.com/celadonasia

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Celadon Capital